BRIEF—Executive changes at GSK's vaccines unit

UK pharma major GlaxoSmithKline yesterday announced that Luc Debruyne, president, Vaccines Division, is to leave GSK at the end of the year.

Roger Connor, currently GSK’s president, Global Manufacturing & Supply (GMS), will become president, Vaccines on September 1.

During a 27-year career at GSK, Mr Debruyne, has held a number of roles including general manager for the company in the Netherlands and Italy and senior vice president of the pharmaceuticals business in Europe. For the last five years he has been president, Vaccines overseeing the successful integration of the Novartis vaccines business, including the R&D portfolios and manufacturing networks, aligning resources to priority projects, preparation of the Shingrix launch and building a stronger presence in the USA.

Roger Connor has been on the corporate executive team (CET) since 2012 as president, GMS and has led the strategic transformation of GSK’s supply chain to support improved quality and supply performance. He has a proven track record of leading a complex, global organisation, developing organisational capability and driving cultural transformation.

With effect from September 1, Regis Simard is appointed president, pharmaceutical supply chain and will join the CET. He is currently SVP global pharma manufacturing and joined GSK in 2005 as a site director in France, having previously worked in the electronics, medical devices and pharmaceutical industries.